アムジェン株式会社は公益財団法人 骨粗鬆症財団（折茂 肇理事長）の令和5年度財団研究助成に対し、前年度に引き続き協賛いたします。本プログラムは、骨粗鬆症の発症およびそれによる骨折を予防し、骨粗鬆症により生じる寝たきりなどの生活の質の低下の改善につながる臨床研究に対し助成を行うもので、現在同財団にある唯一の研究助成プログラムです。アムジェン株式会社はこの趣旨に賛同し、令和２年度から協賛しています。
骨粗鬆症は、骨量の減少と骨質の劣化により骨の強度が低下して、骨折しやすくなる疾患で、加齢や閉経などによって骨吸収と骨形成のバランスが崩れることが原因で発症します。現在、日本における40歳以上の骨粗鬆症の有病者数は1,280万人（男性300万人、女性980万人）と推計されています1。加齢とともに増加し、特に女性に多く、高齢者人口の増加などから将来的にも増加すると推測されています1,2。また、加齢による骨粗鬆症の増加により骨折も増え、60～70歳代にかけて急激に増加します3。発生件数も増え続けており、特に女性の大腿骨近位部骨折の件数は、1987年の3万9,700件から2017年には約3.8倍の14万9,300件にまで増加しています3。
高齢者、特に女性は骨折リスクが高い状態にあり、フレイル（身体的脆弱性のみならず精神・心理的脆弱性や社会的脆弱性、自立障害や死亡を含む健康障害を招きやすい状態）やロコモティブシンドロームとも関連する骨折や、その要因となる骨粗鬆症に積極的にアプローチすることが喫緊の課題として求められています。
本プログラムの対象は、例年通りの骨粗鬆症に関する国内臨床研究に加えて、指定課題として、医療データベースを用いた骨折数に関する疫学研究（研究期間は最長3年間）、骨粗鬆症の予防・検診の普及に関する研究、骨粗鬆症の一次骨折予防に関する研究とし、助成対象期間は令和5年1月～12月の1年間。助成金額は1件あたり100万円（最大10件まで）。骨粗鬆症財団が選抜した医学専門家で構成される選考委員会が審査し理事会での決定を経て、令和4年12月中旬頃に応募者に通知します。募集期間は令和4年8月1日～9月20日（必着）です。尚、協賛企業であるアムジェン社のロモソズマブ、デノスマブに関する研究は対象外としています。
詳細は骨粗鬆症財団のWebサイト新着情報（https://www.jpof.or.jp/）をご覧ください。
アムジェン株式会社について
アムジェン株式会社は、世界最大規模の独立バイオテクノロジー企業である米国アムジェン社の日本法人です。アムジェン株式会社では、循環器疾患、がん、骨疾患、炎症・免疫性疾患、神経疾患を始めとするアンメット・メディカル・ニーズが高い領域に焦点を絞り、現在約700人の従業員が、「To
serve patients – 患者さんのために、今できるすべてを」というミッションのもと、臨床開発から販売までの活動を行っています。詳細については www.amgen.co.jp をご覧になるか、https://www.facebook.com/amgenjapan のフォローをお願い致します。
アムジェン社について
アムジェン社は、革新的な治療薬の発見、開発、製造、提供を通じて、重篤な疾患に苦しむ患者さんのために生物学の可能性を切り拓くことに取り組んでいます。このアプローチは、疾患の複雑性を解明し、人体の生物学上の基本を理解するために、先進的なヒト遺伝学などの手法を活用することから始まります。
アムジェン社は、アンメット・メディカル・ニーズが大きい領域に焦点を絞り、専門知識を活用して、医療効果を向上させ、人々の生活に画期的な改善をもたらすソリューションを追求しています。1980年に創業したバイオテクノロジーのパイオニアであるアムジェン社は、世界最大の独立バイオテクノロジー企業の一社に成長し、世界中の何百万という患者さんに貢献しており、革新的な可能性が期待されるパイプラインを開発しています。
アムジェンはダウ・ジョーンズ工業株価平均を構成する30社のうちの一社であり、ナスダック100指数にも含まれています。2021年には、Fortune and Great Place to WorkTMからWorld's Best WorkplacesTMの25社のうちの一社に、Barron'sから世界で最も持続可能な企業100社のうちの一社に選ばれました。
詳細については www.amgen.comをご覧になるか、www.twitter.com/amgenをフォローしてください。
Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of
Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking
statements, including any statements on the outcome, benefits and synergies of collaborations, or potential
collaborations, with any other company (including BeiGene, Ltd., Kyowa-Kirin Co., Ltd., or any collaboration to
manufacture therapeutic antibodies against COVID-19), the performance of Otezla® (apremilast) (including
anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Five Prime Therapeutics, Inc.
acquisition, or the Teneobio, Inc. acquisition, as well as estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results
or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of
pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, and other such
estimates and results. Forward-looking statements involve significant risks and uncertainties, including those
discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including
our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on
Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does
not undertake any obligation to update any forward-looking statements contained in this document as a result of new
information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.
Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
注意事項（アムジェン株式会社）
このニュースリリースに含まれている医薬品（開発中のものを含む）に関する情報は、宣伝広告、医学的アドバイスを目的とするものではありません。
###
この件に関するお問い合わせ先
アムジェン株式会社（東京）
コーポレート・アフェアーズ
TEL 03-4563-8610
References